药康生物
(688046)
| 流通市值：72.32亿 | | | 总市值：72.32亿 |
| 流通股本：4.10亿 | | | 总股本：4.10亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 522,037,439.43 | 344,988,138.76 | 701,371,554.95 | 490,779,747.31 |
| 交易性金融资产 | 670,253,369.98 | 767,697,876.81 | 467,337,452.06 | 567,252,287.73 |
| 应收票据及应收账款 | 415,219,261.85 | 392,912,399.63 | 350,806,495.58 | 375,995,041.16 |
| 其中：应收票据 | - | 299,999.6 | - | - |
| 应收账款 | 415,219,261.85 | 392,612,400.03 | 350,806,495.58 | 375,995,041.16 |
| 预付款项 | 5,396,397.68 | 7,674,740.18 | 4,562,582.1 | 7,957,577.26 |
| 其他应收款合计 | 5,393,009.06 | 6,591,049.01 | 6,279,399.27 | 8,409,655.77 |
| 其中:应收利息 | - | - | - | 6,326.14 |
| 存货 | 62,563,165.24 | 58,534,609.77 | 54,196,734.18 | 57,943,885.71 |
| 一年内到期的非流动资产 | 22,098,876.52 | 76,742,040.73 | 109,330,342.1 | 152,383,876.21 |
| 其他流动资产 | 78,799,195.87 | 64,280,571.27 | 15,889,284.1 | 17,004,463.9 |
| 流动资产合计 | 1,781,760,715.63 | 1,719,421,426.16 | 1,709,773,844.34 | 1,677,726,535.05 |
| 非流动资产: | | | | |
| 长期股权投资 | 91,625,786.27 | 78,901,011.92 | 80,042,730.26 | 82,337,628.82 |
| 其他权益工具投资 | 8,999,952 | 8,999,952 | 8,999,952 | 500,000 |
| 其他非流动金融资产 | 10,128,082.21 | 10,065,753.43 | 10,004,109.59 | - |
| 投资性房地产 | - | - | - | 7,949,159.99 |
| 固定资产 | 477,741,529.49 | 486,063,001.01 | 493,221,530.68 | 490,452,629.53 |
| 在建工程 | 112,267,165.55 | 99,029,856.36 | 90,852,441.13 | 91,680,094.04 |
| 生产性生物资产 | 7,113,947.75 | 6,835,317.59 | 5,730,187.72 | 6,248,719.88 |
| 使用权资产 | 58,910,426.23 | 65,929,050.37 | 36,471,839.78 | 38,870,813.33 |
| 无形资产 | 47,564,498.8 | 48,550,241.2 | 49,045,963.28 | 45,932,784.87 |
| 开发支出 | 9,361,527.76 | 8,271,120.56 | 6,358,092.61 | 10,917,512.04 |
| 长期待摊费用 | 29,378,185.08 | 31,370,779.38 | 34,222,550.74 | 34,433,863.14 |
| 递延所得税资产 | 39,599,537.13 | 38,493,060.98 | 35,982,138.97 | 43,289,526.09 |
| 其他非流动资产 | 124,039,048.13 | 49,033,762.29 | 11,939,894.55 | 3,201,219.38 |
| 非流动资产合计 | 1,016,729,686.4 | 931,542,907.09 | 862,871,431.31 | 855,813,951.11 |
| 资产总计 | 2,798,490,402.03 | 2,650,964,333.25 | 2,572,645,275.65 | 2,533,540,486.16 |
| 流动负债: | | | | |
| 短期借款 | 240,589,606.23 | 139,546,896.09 | 88,040,399 | 68,088,751.26 |
| 应付票据及应付账款 | 64,809,103.29 | 65,647,143.05 | 72,175,024.01 | 89,652,692.78 |
| 应付账款 | 64,809,103.29 | 65,647,143.05 | 72,175,024.01 | 89,652,692.78 |
| 合同负债 | 134,238,146.53 | 133,829,803.42 | 138,225,648.01 | 108,184,802.08 |
| 应付职工薪酬 | 33,279,578.35 | 28,180,738.89 | 50,060,232.24 | 37,537,835.94 |
| 应交税费 | 7,549,826.24 | 6,414,399.01 | 4,514,338.73 | 6,088,939.87 |
| 其他应付款合计 | 51,385,161.63 | 9,955,786.08 | 9,360,340.96 | 21,914,517.19 |
| 应付股利 | 44,988,970.18 | - | - | 12,254,340.75 |
| 一年内到期的非流动负债 | 11,906,543.29 | 14,402,005.64 | 8,819,637.38 | 9,917,420.51 |
| 流动负债平衡项目 | 0 | -0.01 | 0 | 0 |
| 流动负债合计 | 543,757,965.56 | 397,976,772.17 | 371,195,620.33 | 341,384,959.63 |
| 非流动负债: | | | | |
| 租赁负债 | 57,317,990.93 | 61,893,839.16 | 35,621,508.96 | 35,818,708.3 |
| 递延收益 | 20,493,001.11 | 21,229,871.02 | 22,902,740.95 | 24,810,610.86 |
| 递延所得税负债 | 9,009,276.04 | 7,942,517.26 | 8,199,085.8 | 8,212,017.24 |
| 非流动负债合计 | 86,820,268.08 | 91,066,227.44 | 66,723,335.71 | 68,841,336.4 |
| 负债合计 | 630,578,233.64 | 489,042,999.61 | 437,918,956.04 | 410,226,296.03 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 410,000,000 | 410,000,000 | 410,000,000 | 410,000,000 |
| 资本公积 | 1,251,028,660.71 | 1,261,606,295.2 | 1,261,144,258.89 | 1,260,289,196.99 |
| 减:库存股 | 14,730,302.94 | 35,819,316.32 | 32,670,348.88 | 23,869,236.73 |
| 其他综合收益 | 8,084,054.89 | 8,540,845.59 | 8,639,160.83 | 886,421.8 |
| 盈余公积 | 52,305,892.22 | 52,305,892.22 | 52,305,892.22 | 43,553,007.48 |
| 未分配利润 | 461,223,863.51 | 465,287,616.95 | 435,307,356.55 | 432,454,800.6 |
| 归属于母公司股东权益合计 | 2,167,912,168.39 | 2,161,921,333.64 | 2,134,726,319.61 | 2,123,314,190.14 |
| 股东权益合计 | 2,167,912,168.39 | 2,161,921,333.64 | 2,134,726,319.61 | 2,123,314,190.14 |
| 负债和股东权益合计 | 2,798,490,402.03 | 2,650,964,333.25 | 2,572,645,275.65 | 2,533,540,486.16 |
| 公告日期 | 2025-08-23 | 2025-04-26 | 2025-04-26 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |